{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-292225","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2021-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.895679+00:00","generated_at":"2026-06-28T23:07:48.911371+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xeris Biopharma closes merger with Strongbridge; appoints new board and officers","bullets":["Board expanded from 1 to 8 directors; members include prior directors from Xeris and Strongbridge.","New officers: John Shannon as President/COO, Kenneth Johnson as SVP Global Development, Beth Hecht as Chief Legal Officer, Steven Prestrelski as Chief Scientific Officer.","CEO Paul Edick gets amended employment: base salary $667,244, target bonus 60%; severance up to 24 months base upon change-in-control termination.","COO Shannon base salary $500,000 with 50% target bonus; CFO Pieper base salary $375,000 with 40% target bonus.","Assumed legacy equity plans from both Xeris (2018 Plan, ESPP, Inducement Plan) and Strongbridge (2015 Plan, Director Plan, 2017 Inducement Plan)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-292225","json":"https://secwatch.observer/filing/0001193125-21-292225.json","markdown":"https://secwatch.observer/filing/0001193125-21-292225.md","text":"https://secwatch.observer/filing/0001193125-21-292225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/d184152d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T23:07:48.911371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"041e0c8d3b","claim":"Dawn Halkuff was appointed as Director at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"21b11cf75b","claim":"John H. Johnson was appointed as Director at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"each of the following members of the Strongbridge board of directors was designated and appointed to the Board: John H. Johnson and Garheng Kong, M.D., PhD, MBA","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"397fb217be","claim":"Steven Prestrelski was appointed as Chief Scientific Officer at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"56ccbb0b33","claim":"BJ Bormann was appointed as Director at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8b6f031b7e","claim":"John Shannon was appointed as President and Chief Operating Officer at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"8ea6f0ff4b","claim":"Beth P. Hecht was appointed as Senior Vice President, Chief Legal Officer & Corporate Secretary at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, Chief Legal Officer & Corporate Secretary"}],"fact_type":"executive_change"},{"claim_id":"8ef332912c","claim":"John Schmid was appointed as Director at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9cc716c227","claim":"Jeffrey W. Sherman was appointed as Director at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d601e601df","claim":"Kenneth Johnson was appointed as Senior Vice President, Global Development and Medical Affairs at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, Global Development and Medical Affairs"}],"fact_type":"executive_change"},{"claim_id":"fb10129f48","claim":"Marla S. Persky was appointed as Director at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fcb9f98c71","claim":"Garheng Kong was appointed as Director at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"each of the following members of the Strongbridge board of directors was designated and appointed to the Board: John H. Johnson and Garheng Kong, M.D., PhD, MBA","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}